<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="303d9134-594c-63c6-e063-6394a90a4edf"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use CEFUROXIME AXETIL TABLETS safely and effectively. See full prescribing information for CEFUROXIME AXETIL TABLETS.
 <br/>
      <br/>
CEFUROXIME AXETIL tablets, for oral use
 <br/>
      <br/>
Initial U.S. Approval: 1987
</title>
   <effectiveTime value="20250313"/>
   <setId root="15cabe73-f39d-4798-a840-115fe94f8f96"/>
   <versionNumber value="24"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="156893695"/>
            <name>PD-Rx Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="156893695"/>
                  <name>PD-Rx Pharmaceuticals, Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="156893695"/>
                        <name>PD-Rx Pharmaceuticals, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72789-035" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="303da43b-587f-6bc7-e063-6394a90ad69d"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250313"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72789-035" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cefuroxime axetil</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cefuroxime axetil</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="67877-216" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="776XM7047L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CALCIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H0G9379FGK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CALCIUM CARBONATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (120 .MU.M)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="LMI26O6933" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALUMINUM OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Z49QDT0J8Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CEFUROXIME AXETIL</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="O1R9FJ93ED" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CEFUROXIME</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72789-035-20" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20191218"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72789-035-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20191218"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="14" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72789-035-14" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230515"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA065496" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20101201"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">203</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="e57f65d7-23eb-f45b-e053-2995a90a19fa"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20211123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Cefuroxime axetil tablet is a cephalosporin antibacterial drug indicated for the treatment of the following infections due to susceptible bacteria: (1)
         
 
    <br/> 
        

   </paragraph>
                        <br/>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pharyngitis/tonsillitis (adults and pediatric patients) (
          
  
     <linkHtml href="#Section_1.1">1.1</linkHtml>) 
         
 
    </item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>Acute bacterial otitis media (pediatric patients) (
          
  
     <linkHtml href="#Section_1.2">1.2</linkHtml>) 
         
 
    </item>
                           <item>Acute bacterial maxillary sinusitis (adults and pediatric patients) (
          
  
     <linkHtml href="#Section_1.3">1.3</linkHtml>)
         
 
    </item>
                           <item>Acute bacterial exacerbations of chronic bronchitis (adults and pediatric patients 13 years and older) (
          
  
     <linkHtml href="#Section_1.4">1.4</linkHtml>) 
         
 
    </item>
                           <item>Uncomplicated skin and skin-structure infections (adults and pediatric patients 13 years and older) (
          
  
     <linkHtml href="#Section_1.5">1.5</linkHtml>) 
         
 
    </item>
                           <item>Uncomplicated urinary tract infections (adults and pediatric patients 13 years and older) (
          
  
     <linkHtml href="#Section_1.6">1.6</linkHtml>) 
         
 
    </item>
                           <item>Uncomplicated gonorrhea (adults and pediatric patients 13 years and older) (
          
  
     <linkHtml href="#Section_1.7">1.7</linkHtml>) 
         
 
    </item>
                           <item>Early Lyme disease (adults and pediatric patients 13 years and older) (
          
  
     <linkHtml href="#Section_1.8">1.8</linkHtml>) 
         
 
    </item>
                        </list>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_1.1">
                     <id root="e57f65d7-23ec-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Pharyngitis/Tonsillitis</title>
                     <text>
                        <paragraph>Cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of 
         
 
  <content styleCode="italics">Streptococcus pyogenes</content>.
         
 
  <br/>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials.</item>
                           <item> The efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of 
          
  
   <content styleCode="italics">Streptococcus pyogenes</content> has not been demonstrated in clinical trials.
         
 
  </item>
                        </list>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.2">
                     <id root="e57f65d7-23ed-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Acute Bacterial Otitis Media</title>
                     <text>
                        <paragraph>Cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of 
         
 
  <content styleCode="italics">Streptococcus pneumoniae, Haemophilus influenzae </content>(including β-lactamase–producing strains), 
         
 
  <content styleCode="italics">Moraxella catarrhalis</content> (including β-lactamase–producing strains), or 
         
 
  <content styleCode="italics">Streptococcus pyogenes</content>.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.3">
                     <id root="e57f65d7-23ee-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Acute Bacterial Maxillary Sinusitis</title>
                     <text>
                        <paragraph>Cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of 
         
 
  <content styleCode="italics">Streptococcus pneumoniae </content>or 
         
 
  <content styleCode="italics">Haemophilus influenzae </content>(non
         
 
  <content styleCode="italics">-β</content>-lactamase–producing strains only).
         
 
  <br/>
                           <content styleCode="underline">Limitations of Use </content>
                           <br/> The effectiveness of Cefuroxime axetil for sinus infections caused by β-lactamase–producing 
         
 
  <content styleCode="italics">Haemophilus influenzae </content>or 
         
 
  <content styleCode="italics">Moraxella catarrhalis </content>in patients with acute bacterial maxillary sinusitis was not established due to insufficient numbers of these isolates in the clinical trials 
         
 
  <content styleCode="italics">[see Clinical Studies (
          
  
   <linkHtml href="#Section_14.1">14.1</linkHtml>)]
         
 
  </content>.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.4">
                     <id root="e57f65d7-23ef-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.4 Acute Bacterial Exacerbations of Chronic Bronchitis </title>
                     <text>
                        <paragraph>Cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with mild-to-moderate acute bacterial exacerbations of chronic bronchitis caused by susceptible strains of 
         
 
  <content styleCode="italics">Streptococcus pneumoniae</content>, 
         
 
  <content styleCode="italics">Haemophilus influenzae </content>(β-lactamase–negative strains), or 
         
 
  <content styleCode="italics">Haemophilus parainfluenzae </content>(β-lactamase–negative strains).
        

 </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.5">
                     <id root="e57f65d7-23f0-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.5 Uncomplicated Skin and Skin-Structure Infections</title>
                     <text>
                        <paragraph>Cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with uncomplicated skin and skin-structure infections caused by susceptible strains of 
         
 
  <content styleCode="italics">Staphylococcus aureus </content>(including β
         
 
  <content styleCode="italics">-</content>lactamase–producing strains) or 
         
 
  <content styleCode="italics">Streptococcus pyogenes.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.6">
                     <id root="e57f65d7-23f1-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.6 Uncomplicated Urinary Tract Infections</title>
                     <text>
                        <paragraph>Cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with uncomplicated urinary tract infections caused by susceptible strains of 
         
 
  <content styleCode="italics">Escherichia coli </content>or 
         
 
  <content styleCode="italics">Klebsiella pneumoniae</content>.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.7">
                     <id root="e57f65d7-23f2-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.7 Uncomplicated Gonorrhea</title>
                     <text>
                        <paragraph>Cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with uncomplicated gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing susceptible strains of 
         
 
  <content styleCode="italics">Neisseria gonorrhoeae </content>and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing susceptible strains of 
         
 
  <content styleCode="italics">Neisseria gonorrhoeae</content>.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.8">
                     <id root="e57f65d7-23f3-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.8 Early Lyme Disease (erythema migrans)</title>
                     <text>
                        <paragraph>Cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with early Lyme disease (erythema migrans) caused by susceptible strains of 
         
 
  <content styleCode="italics">Borrelia burgdorferi.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.9">
                     <id root="e57f65d7-23f4-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.10 Usage</title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="e57fd471-29f2-b3dd-e053-2a95a90ab890"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20211123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Tablets and oral suspension are not bioequivalent and are therefore not substitutable on a milligram-per-milligram basis. ( 
     <linkHtml href="#Section_2.1">2.1</linkHtml>)
    </item>
                           <item>Administer tablets with or without food. ( 
     <linkHtml href="#Section_2.2">2.2</linkHtml>)
    </item>
                           <item>Administer cefuroxime axetil tablets as described in the dosage guidelines. ( 
     <linkHtml href="#Section_2.2">2.2</linkHtml>)
    </item>
                           <item>Dosage adjustment is required for patients with impaired renal function. ( 
     <linkHtml href="#Section_2.3">2.5</linkHtml>)
     <br/>
                              <table border="0" cellpadding="0" cellspacing="0" width="340">
                                 <colgroup>
                                    <col width="53.9589442815249%"/>
                                    <col width="23.4604105571848%"/>
                                    <col width="22.5806451612903%"/>
                                 </colgroup>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">Adult Patients and Pediatric Patients Dosage Guidelines for </content>
                                          <content styleCode="bold">Cefuroxime Axetil</content>
                                          <content styleCode="bold"> Tablets</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">Infection</content>
                                          <br/>
                                       </td>
                                       <td colspan="2" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Dosage</content>
                                          <br/>
                                       </td>
                                       <td styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Duration (Days)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">Adults and Adolescents (13 years and older)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Pharyngitis/tonsillitis (mild to moderate)
         <br/>
                                       </td>
                                       <td styleCode="Rrule" valign="top">250 mg
         <br/>
                                          <br/>
				every 12 hours
         <br/>
                                       </td>
                                       <td colspan="2" styleCode="Rrule" valign="top">10
         <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Acute bacterial maxillary sinusitis (mild to moderate)
         <br/>
                                       </td>
                                       <td styleCode="Rrule" valign="top">250 mg
         <br/>
                                          <br/>
				every 12 hours
         <br/>
                                       </td>
                                       <td colspan="2" styleCode="Rrule" valign="top">10
         <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Acute bacterial exacerbations of chronic bronchitis (mild to moderate)
         <br/>
                                       </td>
                                       <td styleCode="Rrule" valign="top">250 or 500 mg every 12 hours
         <br/>
                                       </td>
                                       <td colspan="2" styleCode="Rrule" valign="top">10
         <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Uncomplicated skin and skin-structure infections
         <br/>
                                       </td>
                                       <td styleCode="Rrule" valign="top">250 or 500 mg every 12 hours
         <br/>
                                       </td>
                                       <td colspan="2" styleCode="Rrule" valign="top">10
         <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Uncomplicated urinary tract infections
         <br/>
                                       </td>
                                       <td styleCode="Rrule" valign="top">250 mg
         <br/>
                                          <br/>
				every 12 hours
         <br/>
                                       </td>
                                       <td colspan="2" styleCode="Rrule" valign="top">7 to 10
         <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Uncomplicated gonorrhea
         <br/>
                                       </td>
                                       <td styleCode="Rrule" valign="top">1,000 mg
         <br/>
                                       </td>
                                       <td colspan="2" styleCode="Rrule" valign="top">single dose
         <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Early Lyme disease
         <br/>
                                       </td>
                                       <td styleCode="Rrule" valign="top">500 mg
         <br/>
                                          <br/>
				every 12 hours
         <br/>
                                       </td>
                                       <td colspan="2" styleCode="Rrule" valign="top">20
         <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">Pediatric Patients younger than 13 years (who can swallow tablets whole</content>)
         <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Acute bacterial otitis media
         <br/>
                                       </td>
                                       <td styleCode="Rrule" valign="top">250 mg
         <br/>
                                          <br/>
				every 12 hours
         <br/>
                                       </td>
                                       <td colspan="2" styleCode="Rrule" valign="top">10
         <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule" valign="top">Acute bacterial maxillary sinusitis
         <br/>
                                       </td>
                                       <td styleCode="Rrule" valign="top">250 mg
         <br/>
                                          <br/>
				every 12 hours
         <br/>
                                       </td>
                                       <td colspan="2" styleCode="Rrule" valign="top">10
         <br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <br/>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="e57f65d7-23f6-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Administration Instructions</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are therefore not substitutable on a milligram-per-milligram basis 
          
  
   <content styleCode="italics">[see Clinical Pharmacology (
           
   
    <linkHtml href="#Section_12.3">12.3</linkHtml>)].
          
  
   </content>
                           </item>
                           <item>Administer cefuroxime axetil tablets as described in the appropriate dosage guidelines 
          
  
   <content styleCode="italics">[see Dosage and Administration (
           
   
    <linkHtml href="#Section_2.2">2.2</linkHtml>)]. 
          
  
   </content>
                           </item>
                           <item>Administer cefuroxime axetil tablets with or without food. </item>
                           <item>Pediatric patients (aged 13 years and older) who cannot swallow the cefuroxime axetil tablets whole should receive cefuroxime axetil for oral suspension because the tablet has a strong, persistent bitter taste when crushed 
          
  
   <content styleCode="italics">[see Dosage and Administration (
           
   
    <linkHtml href="#Section_2.2">2.2</linkHtml>)].
          
  
   </content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="e57f65d7-23f7-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage for Cefuroxime axetil Tablets</title>
                     <text>
                        <paragraph> Administer cefuroxime axetil tablets as described in the dosage guidelines table below with or without food.
         
 
  <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1. Adult Patients and Pediatric Patients Dosage Guidelines for Cefuroxime Axetil Tablets</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="295.659">
                           <col width="33.3333333333333%"/>
                           <col width="33.3333333333333%"/>
                           <col width="33.3333333333333%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> 
            
    
     <content styleCode="bold">Infection</content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Dosage</content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Duration (Days)</content>
                                    <br/> 
           
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule" valign="top"> 
            
    
     <content styleCode="bold">Adults and Adolescents (13 years and older)</content>
                                    <br/> 
           
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Pharyngitis/tonsillitis (mild to moderate)
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 250 mg every 12 hours
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 10
            
    
     <br/> 
           
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Acute bacterial maxillary sinusitis (mild to moderate)
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 250 mg every 12 hours
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 10
            
    
     <br/> 
           
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Acute bacterial exacerbations of chronic bronchitis(mild to moderate  )
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top"> 250 or 500 mg every 12 hours </td>
                                 <td styleCode="Rrule" valign="top"> 10a
            
    
     <br/> 
           
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Uncomplicated skin and skin-structure infections
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 250 or 500 mg every 12 hours
            
    
     <br/>  
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 10
            
    
     <br/> 
           
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Uncomplicated urinary tract infections
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 250 mg every 12 hours
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 7 to 10
            
    
     <br/> 
           
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Uncomplicated gonorrhea
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 1,000 mg
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> single dose
            
    
     <br/> 
           
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Early Lyme disease
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 500 mg every 12 hours
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 20
            
    
     <br/> 
           
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule" valign="top"> 
            
    
     <content styleCode="bold">Pediatric Patients younger than 13 years (who can swallow tablets whole)
             
     
      <sup> b</sup>
                                    </content>
                                    <br/> 
           
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Acute bacterial otitis media
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 250 mg every 12 hours
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 10
            
    
     <br/> 
           
   
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> Acute bacterial maxillary sinusitis
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 250 mg every 12 hours
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 10
            
    
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>a The safety and effectiveness of cefuroxime axetil administered for less than 10 days in patients with acute exacerbations of chronic bronchitis have not been established.
         
 
  <br/>b When crushed, the tablet has a strong, persistent bitter taste. Therefore, patients who cannot swallow the tablet whole should receive the oral suspension.
        

 </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="e57f65d7-23f8-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dosage in Patients with Impaired Renal Function</title>
                     <text>
                        <paragraph>A dosage interval adjustment is required for patients whose creatinine clearance is less than 30 mL/min, as listed in Table 4 below, because cefuroxime is eliminated primarily by the kidney 
         
 
  <content styleCode="italics">[see Clinical Pharmacology (
          
  
   <linkHtml href="#Section_12.3">12.3</linkHtml>)].
          
  
   <br/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 4. Dosing in Adults with Renal Impairment
          
  
   <br/>
                           </content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="582">
                           <col width="32.2502493943281%"/>
                           <col width="67.7497506056719%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Creatinine Clearance (mL/min) </content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">Recommended Dosage </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">≥30 
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">No dosage adjustment 
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">10 to ˂30 
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">Standard individual dose given every 24 hours 
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">˂10 (without hemodialysis)
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">Standard individual dose given every 48 hours 
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Hemodialysis 
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">A single additional standard dose should be given at the end of each dialysis 
            
    
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="e57f65d7-23f9-f45b-e053-2995a90a19fa"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Cefuroxime axetil tablets,USP 250 mg of cefuroxime (as cefuroxime axetil), are blue, capsule-shaped, biconvex, film-coated tablets with “204” debossed on one side and plain on the other side.</paragraph>
                  <paragraph>Cefuroxime Axetil Tablets,USP 500 mg of cefuroxime (as cefuroxime axetil), are blue, capsule-shaped, biconvex, film-coated tablets with 203” debossed on one side and plain on the other side.</paragraph>
               </text>
               <effectiveTime value="20211123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Tablets: 250 mg and 500 mg  </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="e57f65d7-23fa-f45b-e053-2995a90a19fa"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Cefuroxime axetil is contraindicated in patients with a known hypersensitivity (e.g., anaphylaxis) to cefuroxime axetil or to other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins).</paragraph>
               </text>
               <effectiveTime value="20211123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Known hypersensitivity (e.g., anaphylaxis) to cefuroxime axetil or to other β-lactams (e.g., penicillins and cephalosporins). </paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="e57f65d7-23fb-f45b-e053-2995a90a19fa"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20211123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Serious hypersensitivity (anaphylactic) reactions: In the event of a serious reaction, discontinue cefuroxime axetil and institute appropriate therapy. (
          
  
     <linkHtml href="#Section_5.1">5.1</linkHtml>)
         
 
    </item>
                           <item> 
          
  
     <content styleCode="italics">
                                 <content styleCode="italics">Clostridioides</content> difficile
          
  
     </content>-associated diarrhea (CDAD): If diarrhea occurs, evaluate patients for CDAD. (
          
  
     <linkHtml href="#Section_5.2">5.2</linkHtml>)
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="e57f65d7-23fc-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Anaphylactic Reactions</title>
                     <text>
                        <paragraph>Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on β-lactam antibacterials, including cefuroxime axetil 
         
 
  <content styleCode="italics">[see Adverse Reactions (
          
  
   <linkHtml href="#Section_6.2">6.2</linkHtml>)]
         
 
  </content>. These reactions are more likely to occur in individuals with a history of β-lactam hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Cefuroxime axetil is contraindicated in patients with a known hypersensitivity to cefuroxime axetil or other β-lactam antibacterial drugs 
         
 
  <content styleCode="italics">[see Contraindications (
          
  
   <linkHtml href="#Section_4">4</linkHtml>)]
         
 
  </content>. Before initiating therapy with cefuroxime axetil, inquire about previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. If an allergic reaction occurs, discontinue cefuroxime axetil and institute appropriate therapy.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="e57f65d7-23fd-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 
        

 <content styleCode="italics">Clostridioides difficile</content>-Associated Diarrhea
       
</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="italics">Clostridioides </content>difficile-
         
 
  </content>associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefuroxime axetil, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of 
         
 
  <content styleCode="italics">C. difficile</content>.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile </content>produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of 
         
 
  <content styleCode="italics">C. difficile </content>cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.
         
 
  <br/>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against 
         
 
  <content styleCode="italics">C. difficile </content>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of 
         
 
  <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="e57f65d7-23fe-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Potential for Microbial Overgrowth</title>
                     <text>
                        <paragraph>The possibility of superinfections with fungal or bacterial pathogens should be considered during therapy.</paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="e57f65d7-23ff-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Development of Drug-Resistant Bacteria</title>
                     <text>
                        <paragraph>Prescribing cefuroxime axetil either in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="e57f65d7-2400-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Interference with Glucose Tests</title>
                     <text>
                        <paragraph>A false-positive result for glucose in the urine may occur with copper reduction tests, and a false-negative result for blood/plasma glucose may occur with ferricyanide tests in subjects receiving cefuroxime axetil 
         
 
  <content styleCode="italics">[see Drug Interactions (
          
  
   <linkHtml href="#Section_7.4">7.3)</linkHtml>]
         
 
  </content>.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="e57f65d7-2401-f45b-e053-2995a90a19fa"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious and otherwise important adverse reaction is described in greater detail in the Warnings and Precautions section of the label: </paragraph>
                  <paragraph>Anaphylactic Reactions 
       
 
  <content styleCode="italics">[see Warnings and Precautions (
        
  
   <linkHtml href="#Section_5.1">5.1</linkHtml>)].
       
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20211123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (≥3%) for cefuroxime axetil tablets are diarrhea, nausea/vomiting, Jarisch-Herxheimer reaction, and vaginitis (early Lyme disease). (
         
 
    <linkHtml href="#Section_6.1">6.1</linkHtml>)
         
 
    <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, </content>
                           <content styleCode="bold">contact Ascend Laboratories, LLC at 1-877-ASC-RX01 (877-272-7901)</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or 
          
  
     <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                           </content>.
        

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="e57f65d7-2402-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
         
 
  <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Tablets </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Multiple-Dose Dosing Regimens with 7 to 10 Days’ Duration</content>: In multiple-dose clinical trials, 912 subjects were treated with cefuroxime axetil (125 to 500 mg twice daily). It is noted that 125 mg twice daily is not an approved dosage. Twenty (2.2%) subjects discontinued medication due to adverse reactions. Seventeen (85%) of the 20 subjects who discontinued therapy did so because of gastrointestinal disturbances, including diarrhea, nausea, vomiting, and abdominal pain. The percentage of subjects treated with cefuroxime axetil who discontinued study drug because of adverse reactions was similar at daily doses of 1,000, 500, and 250 mg (2.3%, 2.1%, and 2.2%, respectively). However, the incidence of gastrointestinal adverse reactions increased with the higher recommended doses.
        

 </paragraph>
                        <paragraph>The adverse reactions in Table 5 are for subjects (n = 912) treated with cefuroxime axetil in multiple-dose clinical trials.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 5. Adverse Reactions (≥1%) after Multiple-Dose Regimens with Cefuroxime Axetil Tablets
          
  
   <br/>
                           </content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="500">
                           <col width="58.1634013061442%"/>
                           <col width="41.8365986938558%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Adverse Reaction</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Cefuroxime Axetil  (n = 912)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Blood and lymphatic system disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top"> 
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Eosinophilia
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">1%
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top"> 
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Diarrhea
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">4%
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Nausea/Vomiting
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">3%
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Investigations</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top"> 
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Transient elevation in AST
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">2%
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Transient elevation in ALT
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">2%
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Transient elevation in LDH
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">1%
            
    
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The following adverse reactions occurred in less than 1% but greater than 0.1% of subjects (n = 912) treated with cefuroxime axetil in multiple-dose clinical trials.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders:</content>
                           <content styleCode="italics"/>Hives, swollen tongue. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Metabolism and Nutrition Disorders:</content>
                           <content styleCode="italics"/>Anorexia. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Nervous System Disorders:</content>
                           <content styleCode="italics"/>Headache. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Cardiac Disorders:</content>
                           <content styleCode="italics"/>Chest pain. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Respiratory Disorders:</content>
                           <content styleCode="italics"/>Shortness of breath. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Gastrointestinal Disorders:</content>
                           <content styleCode="italics"/>Abdominal pain, abdominal cramps, flatulence, indigestion, mouth ulcers. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Skin and Subcutaneous Tissue Disorders:</content>
                           <content styleCode="italics"/>Rash, itch.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Renal and Urinary Disorders:</content>
                           <content styleCode="italics"/>Dysuria. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Reproductive System and Breast Disorders:</content>
                           <content styleCode="italics"/>Vaginitis, vulvar itch. 
         
 
  <br/>
                           <content styleCode="italics"> General Disorders and Administration Site Conditions:</content>
                           <content styleCode="italics"/>Chills, sleepiness, thirst. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Investigations:</content>
                           <content styleCode="italics"/>Positive Coombs’ test.
         
 
  <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Early Lyme Disease with 20-Day Regimen:</content>
                           <content styleCode="italics"/>Two multicenter trials assessed cefuroxime axetil tablets 500 mg twice daily for 20 days. The most common drug-related adverse experiences were diarrhea (10.6%), Jarisch-Herxheimer reaction (5.6%), and vaginitis (5.4%). Other adverse experiences occurred with frequencies comparable to those reported with 7 to 10 days’ dosing.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Single-Dose Regimen for Uncomplicated Gonorrhea:</content>
                           <content styleCode="italics"/>In clinical trials using a single 1,000-mg dose of cefuroxime axetil, 1,061 subjects were treated for uncomplicated gonorrhea.
        

 </paragraph>
                        <paragraph>The adverse reactions in Table 6 were for subjects treated with a single dose of 1,000 mg cefuroxime axetil in U.S. clinical trials.
         
 
  <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 6. Adverse Reactions (≥1%) after Single-Dose Regimen with 1,000-mg Cefuroxime Axetil Tablets for Uncomplicated Gonorrhea
          
  
   <br/>
                           </content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="582">
                           <col width="49.9928744477697%"/>
                           <col width="50.0071255522303%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Adverse Reaction</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Cefuroxime axetil  (n = 1,061)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top"> 
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Nausea/Vomiting
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">7%
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Diarrhea
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">4%
            
    
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>The following adverse reactions occurred in less than 1% but greater than 0.1% of subjects (n = 1,061) treated with a single dose of cefuroxime axetil 1,000 mg for uncomplicated gonorrhea in U.S. clinical trials.</paragraph>
                        <paragraph>
                           <content styleCode="italics"> Infections and Infestations:</content>
                           <content styleCode="italics"/>Vaginal candidiasis. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Nervous System Disorders:</content>
                           <content styleCode="italics"/>Headache, dizziness, somnolence. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Cardiac Disorders:</content>
                           <content styleCode="italics"/>Tightness/pain in chest, tachycardia. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Gastrointestinal Disorders:</content>
                           <content styleCode="italics"/>Abdominal pain, dyspepsia. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Skin and Subcutaneous Tissue Disorders:</content>
                           <content styleCode="italics"/>Erythema, rash, pruritus.
         
 
  <br/>
                           <content styleCode="italics"> Musculoskeletal and Connective Tissue Disorders:</content>
                           <content styleCode="italics"/>Muscle cramps, muscle stiffness, muscle spasm of neck, lockjaw-type reaction. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Renal and Urinary Disorders:</content>
                           <content styleCode="italics"/>Bleeding/pain in urethra, kidney pain. 
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Reproductive System and Breast Disorders:</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>
                        </paragraph>
                        <paragraph>Vaginal itch, vaginal discharge.</paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="e57f65d7-2403-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of cefuroxime axetil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Blood and Lymphatic System Disorders</content>
                           <content styleCode="underline"> </content>
                        </paragraph>
                        <paragraph>Hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia.
         
 
  <content styleCode="underline"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Gastrointestinal Disorders</content>
                        </paragraph>
                        <paragraph>Pseudomembranous colitis 
         
 
  <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hepatobiliary Disorders</content>
                        </paragraph>
                        <paragraph>Hepatic impairment including hepatitis and cholestasis, jaundice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Immune System Disorders</content>
                        </paragraph>
                        <paragraph>Anaphylaxis, serum sickness-like reaction, acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Investigations</content>
                        </paragraph>
                        <paragraph>Increased prothrombin time.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Nervous System Disorders</content>
                        </paragraph>
                        <paragraph>Seizure, encephalopathy. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Renal and Urinary Disorders</content>
                        </paragraph>
                        <paragraph>Renal dysfunction. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Skin and Subcutaneous Tissue Disorders</content>
                        </paragraph>
                        <paragraph>Angioedema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria.</paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="e57f65d7-2404-f45b-e053-2995a90a19fa"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20211123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Drugs that reduce gastric acidity may lower the bioavailability of cefuroxime axetil. (
          
  
     <linkHtml href="#Section_7.2">7.1</linkHtml>) 
         
 
    </item>
                           <item>Coadministration with probenecid increases systemic exposure to cefuroxime axetil and is therefore not recommended. (
          
  
     <linkHtml href="#Section_7.3">7.2</linkHtml>)
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_7.2">
                     <id root="e57f65d7-2405-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Drugs that Reduce Gastric Acidity</title>
                     <text>
                        <paragraph>Drugs that reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with administration in the fasting state. Administration of drugs that reduce gastric acidity may negate the food effect of increased absorption of cefuroxime axetil when administered in the postprandial state. Administer cefuroxime axetil at least 1 hour before or 2 hours after administration of short-acting antacids. Histamine-2 (H2) antagonists and proton pump inhibitors should be avoided.</paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.3">
                     <id root="e57f65d7-2406-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Probenecid</title>
                     <text>
                        <paragraph>Concomitant administration of probenecid with cefuroxime axetil tablets increases serum concentrations of cefuroxime 
         
 
  <content styleCode="italics">[see Clinical Pharmacology (
          
  
   <linkHtml href="#Section_12.3">12.3</linkHtml>)]. 
         
 
  </content>Coadministration of probenecid with cefuroxime axetil is not recommended.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.4">
                     <id root="e57f65d7-2407-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph>A false-positive reaction for glucose in the urine may occur with copper reduction tests (e.g., Benedict's or Fehling's solution), but not with enzyme-based tests for glycosuria. As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood/plasma glucose levels in patients receiving cefuroxime axetil. The presence of cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method.</paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="e57f65d7-2408-f45b-e053-2995a90a19fa"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20211123"/>
               <component>
                  <section ID="Section_8.1">
                     <id root="e57f65d7-2409-f45b-e053-2995a90a19fa"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content> 
        

 </paragraph>
                        <br/>
                        <paragraph>Available data from published epidemiologic studies, case series, and case reports over several decades with cephalosporin use, including  cefuroxime axetil, in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes 
         
 
  <content styleCode="italics">(see Data)</content>. 
        

 </paragraph>
                        <br/>
                        <paragraph>In studies in pregnant mice and rats administered oral cefuroxime axetil during organogenesis at 14 and 9 times the maximum recommended human dose (MRHD) based on body surface area, respectively, there were no adverse developmental outcomes 
         
 
  <content styleCode="italics">(see Data).</content>
                           <content styleCode="italics"> </content>The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. 
        

 </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations 
          
  
   <br/>
                           </content>
                           <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk: </content>Maternal gonorrhea may be associated with preterm birth, low neonatal birth weight, chorioamnionitis, intrauterine growth restriction, small for gestational age, and premature rupture of membranes. Perinatal transmission of gonorrhea to the offspring can result in infant blindness, joint infections, and bloodstream infections. 
        

 </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Data 
          
  
   <br/>
                           </content>
                           <content styleCode="italics">Human Data: </content>While available studies cannot definitively establish the absence of risk, published data from epidemiologic studies, case series, and case reports over several decades have not identified an association with cephalosporin use (including  cefuroxime axetil) during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups. 
         
 
  <content styleCode="italics"> Animal Data: </content>Studies performed with oral cefuroxime axetil administered to pregnant mice during organogenesis (Gestation Days 7 through 16) at doses up to 3,200 mg/kg/day (14 times the MRHD based on body surface area); and in rats dosed during organogenesis and lactation (Gestation Days 7 through 16 and Gestation Days 17 through Lactation Day 21, respectively) at doses up to 1,000 mg/kg/day (9 times the MRHD based on body surface area) have revealed no adverse developmental outcomes. 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.7">
                     <id root="e57f65d7-240a-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content> 
        

 </paragraph>
                        <paragraph>Based on several published case reports describing multiple lactating women who received cefuroxime via intravenous, intramuscular, and oral routes, cefuroxime is present in human milk. The highest maternal milk concentration described occurred in lactating women 8 hours after an intramuscular administration of cefuroxime 750 mg. Allowing for an infant milk consumption of 150 mL/kg/day, the estimated breastfed infant dose would be less than 1% of the adult dose
         
 
  <content styleCode="italics">. </content>No data are available on the effects of the drug on the breastfed infant or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for cefuroxime and any potential adverse effects on the breastfed infant from cefuroxime or from the underlying maternal condition. 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="e57f65d7-240b-f45b-e053-2995a90a19fa"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of cefuroxime axetil have been established for pediatric patients aged 3 months to 12 years for acute bacterial maxillary sinusitis based upon its approval in adults. Use of cefuroxime axetil in pediatric patients is supported by pharmacokinetic and safety data in adults and pediatric patients, and by clinical and microbiological data from adequate and well-controlled trials of the treatment of acute bacterial maxillary sinusitis in adults and of acute otitis media with effusion in pediatric patients. It is also supported by postmarketing adverse events surveillance. 
         
 
  <content styleCode="italics">[See Indications and Usage (
          
  
   <linkHtml href="#Section_1">1</linkHtml>), Dosage and Administration (
          
  
   <linkHtml href="#Section_2">2</linkHtml>), Adverse Reactions (6), Clinical Pharmacology (
          
  
   <linkHtml href="#Section_12.3">12.3</linkHtml>).]
         
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="e57f65d7-240c-f45b-e053-2995a90a19fa"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the total number of subjects who received cefuroxime axetil in 20 clinical trials, 375 were aged 65 and older while 151 were aged 75 and older. No overall differences in safety or effectiveness were observed between these subjects and younger adult subjects. Reported clinical experience has not identified differences in responses between the elderly and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                        <paragraph>Cefuroxime is substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="e57f65d7-240d-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Reducing the dosage of cefuroxime axetil is recommended for adult patients with severe renal impairment (creatinine clearance &lt;30 mL/min) 
         
 
  <content styleCode="italics">[see Dosage and Administration (
          
  
   <linkHtml href="#Section_2.3">2.5</linkHtml>), Clinical Pharmacology (
          
  
   <linkHtml href="#Section_12.3">12.3</linkHtml>)]
         
 
  </content>.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="e57f65d7-240e-f45b-e053-2995a90a19fa"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Overdosage of cephalosporins can cause cerebral irritation leading to convulsions or encephalopathy. Serum levels of cefuroxime can be reduced by hemodialysis and peritoneal dialysis.</paragraph>
               </text>
               <effectiveTime value="20211123"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="e57f65d7-240f-f45b-e053-2995a90a19fa"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <br/>
                  <paragraph>Cefuroxime axetil tablets, USP contain cefuroxime as cefuroxime axetil. Cefuroxime axetil is a semisynthetic, cephalosporin antibacterial drug for oral administration. </paragraph>
                  <paragraph>The chemical name of cefuroxime axetil (1-(acetyloxy) ethyl ester of cefuroxime) is (
       
 
  <content styleCode="italics">RS</content>)-1 hydroxyethyl (6
       
 
  <content styleCode="italics">R</content>,7
       
 
  <content styleCode="italics">R</content>)-7-[2-(2-furyl)glyoxyl-amido]-3-(hydroxymethyl)-8-oxo-5-thia-1 azabicyclo[4.2.0]-oct-2-ene-2-carboxylate, 72-(
       
 
  <content styleCode="italics">Z</content>)-(
       
 
  <content styleCode="italics">O</content>-methyl-oxime), 1-acetate 3-carbamate. Its molecular formula is C
       
 
  <sub>20</sub>H
       
 
  <sub>22</sub>N
       
 
  <sub>4</sub>O
       
 
  <sub>10</sub>S, and it has a molecular weight of 510.48. 
      

 </paragraph>
                  <paragraph>Cefuroxime axetil is in the amorphous form and has the following structural formula:</paragraph>
                  <br/>
                  <renderMultiMedia referencedObject="MM1"/>
                  <br/>
                  <paragraph>Cefuroxime axetil tablets, USP are film-coated and contain the equivalent of 250 or 500 mg of cefuroxime as cefuroxime axetil. Cefuroxime axetil tablets, USP contain the inactive ingredients microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide, calcium stearate, calcium carbonate, crospovidone, hypromellose, titanium dioxide, propylene glycol, FD &amp;C blue no.1 Aluminium lake.</paragraph>
               </text>
               <effectiveTime value="20211123"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>cefuroxime-structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cefuroxime-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="e57f65d7-2410-f45b-e053-2995a90a19fa"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20211123"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="e57f65d7-2411-f45b-e053-2995a90a19fa"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Cefuroxime axetil is an antibacterial drug 
         
 
  <content styleCode="italics">[see Microbiology (
          
  
   <linkHtml href="#Section_12.4">12.4</linkHtml>)].
         
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="e57f65d7-2412-f45b-e053-2995a90a19fa"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                           <content styleCode="bold"/>
                        </paragraph>
                        <paragraph>After oral administration, cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to cefuroxime. Serum pharmacokinetic parameters for cefuroxime following administration of cefuroxime axetil tablets to adults are shown in Table 8.</paragraph>
                        <paragraph>
                           <content styleCode="bold"> Table 8. Pharmacokinetics of Cefuroxime Administered in the Postprandial State as Cefuroxime Axetil Tablets to Adults
          
  
   <sup>a</sup>
                           </content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="609.4725">
                           <col width="19.6617566830333%"/>
                           <col width="21.4729950900164%"/>
                           <col width="21.4729950900164%"/>
                           <col width="18.3960720130933%"/>
                           <col width="18.9961811238407%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Doseb (Cefuroxime</content>
                                    <br/>
                                    <content styleCode="bold">Equivalent)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Peak Plasma</content>
                                    <br/>
                                    <content styleCode="bold">Concentration</content>
                                    <br/>
                                    <content styleCode="bold">(mcg/mL)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Time of Peak</content>
                                    <br/>
                                    <content styleCode="bold">Plasma</content>
                                    <br/>
                                    <content styleCode="bold">Concentration (h)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Mean</content>
                                    <br/>
                                    <content styleCode="bold">Elimination</content>
                                    <br/>
                                    <content styleCode="bold">Half-life (h)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">AUC</content>
                                    <br/>
                                    <content styleCode="bold">(mcg•h/mL)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">125 mg
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">2.1
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">2.2
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">1.2
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">6.7
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">250 mg
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">4.1
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">2.5
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">1.2
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">12.9
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">500 mg
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">7
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">3
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">1.2
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">27.4
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">1,000 mg
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">13.6
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">2.5
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">1.3
            
    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">50
            
    
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup>Mean values of 12 healthy adult volunteers.
        

 </paragraph>
                        <paragraph>
                           <sup>b</sup>Drug administered immediately after a meal.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food:</content> Absorption of the tablet is greater when taken after food (absolute bioavailability increases from 37% to 52%). Despite this difference in absorption, the clinical and bacteriologic responses of subjects were independent of food intake at the time of tablet administration in 2 trials where this was assessed.
        

 </paragraph>
                        <paragraph>All pharmacokinetic and clinical effectiveness and safety trials in pediatric subjects using the suspension formulation were conducted in the fed state. No data are available on the absorption kinetics of the suspension formulation when administered to fasted pediatric subjects.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Lack of Bioequivalence</content>: Oral suspension was not bioequivalent to tablets when tested in healthy adults. The tablet and oral suspension formulations are NOT substitutable on a milligram-per-milligram basis. The area under the curve for the suspension averaged 91% of that for the tablet, and the peak plasma concentration for the suspension averaged 71% of the peak plasma concentration of the tablets. Therefore, the safety and effectiveness of both the tablet and oral suspension formulations were established in separate clinical trials.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                           <content styleCode="bold">
                              <content styleCode="underline"> </content>
                           </content>
                        </paragraph>
                        <paragraph>Cefuroxime is distributed throughout the extracellular fluids. Approximately 50% of serum cefuroxime is bound to protein. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                           <content styleCode="bold">
                              <content styleCode="underline"> </content>
                           </content>
                        </paragraph>
                        <paragraph>The axetil moiety is metabolized to acetaldehyde and acetic acid.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Excretion</content>
                           <content styleCode="bold">
                              <content styleCode="underline"> </content>
                           </content>
                        </paragraph>
                        <paragraph>Cefuroxime is excreted unchanged in the urine; in adults, approximately 50% of the administered dose is recovered in the urine within 12 hours. The pharmacokinetics of cefuroxime in pediatric subjects have not been studied. Until further data are available, the renal elimination of cefuroxime axetil established in adults should not be extrapolated to pediatric subjects.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations </content>
                        </paragraph>
                        <paragraph>Patients with Renal Impairment: In a trial of 28 adults with normal renal function or severe renal impairment (creatinine clearance &lt;30 mL/min), the elimination half-life was prolonged in relation to severity of renal impairment. Prolongation of the dosage interval is recommended in adult patients with creatinine clearance &lt;30 mL/min 
         
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#Section_2.3">2.5</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Geriatric Patients</content>: In a trial of 20 elderly subjects (mean age = 83.9 years) having a mean creatinine clearance of 34.9 mL/min, the mean serum elimination half-life was prolonged to 3.5 hours; however, despite the lower elimination of cefuroxime in geriatric patients, dosage adjustment based on age is not necessary 
         
 
  <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#Section_8.5">8.5</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies </content>
                        </paragraph>
                        <paragraph>Concomitant administration of probenecid with cefuroxime axetil tablets increases the cefuroxime area under the serum concentration versus time curve and maximum serum concentration by 50% and 21%, respectively 
         
 
  <content styleCode="italics">[see Drug Interactions(</content>
                           <content styleCode="italics">
                              <linkHtml href="#Section_7.3">7.2</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.4">
                     <id root="e57f65d7-2413-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action </content>
                        </paragraph>
                        <paragraph>Cefuroxime axetil is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefuroxime axetil has activity in the presence of some β-lactamases, both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Resistance </content>
                        </paragraph>
                        <paragraph>Resistance to cefuroxime axetil is primarily through hydrolysis by β-lactamase, alteration of penicillin-binding proteins (PBPs), decreased permeability, and the presence of bacterial efflux pumps.</paragraph>
                        <paragraph>Susceptibility to cefuroxime axetil will vary with geography and time; local susceptibility data should be consulted, if available. Beta-lactamase
         
 
  <content styleCode="bold">-</content>negative, ampicillin-resistant (BLNAR) isolates of 
         
 
  <content styleCode="italics">H. influenzae </content>should be considered resistant to cefuroxime axetil.
        

 </paragraph>
                        <paragraph>Antimicrobial Activity</paragraph>
                        <paragraph>Cefuroxime axetil has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections 
         
 
  <content styleCode="italics">[see Indications and Usage (
          
  
   <linkHtml href="#Section_1">1</linkHtml>)]
         
 
  </content>:
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Aerobic Bacteria:</content>
                        </paragraph>
                        <paragraph>Gram-positive bacteria 
         
 
  <br/> • Staphylococcus aureus (methicillin-susceptible isolates only)
         
 
  <br/> • Streptococcus pneumoniae 
         
 
  <br/> • Streptococcus pyogenes
        

 </paragraph>
                        <paragraph>Gram-negative bacteria 
         
 
  <br/> • Escherichia colia
         
 
  <br/> • Klebsiella pneumoniaea 
         
 
  <br/> • Haemophilus influenzae 
         
 
  <br/> • Haemophilus parainfluenzae 
         
 
  <br/> • Moraxella catarrhalis 
         
 
  <br/> • Neisseria gonorrhoeae
         
 
  <br/> a Most extended spectrum β-lactamase (ESBL)-producing and carbapenemase-producing isolates are resistant to cefuroxime axetil.
        

 </paragraph>
                        <paragraph>Spirochetes
         
 
  <br/> • Borrelia burgdorferi
         
 
  <br/> The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for cefuroxime against isolates of similar genus or organism group. However, the efficacy of cefuroxime axetil in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Aerobic Bacteria:</content>
                        </paragraph>
                        <paragraph>Gram-positive bacteria
         
 
  <content styleCode="italics">
                              <br/> • Staphylococcus epidermidis (methicillin-susceptible isolates only)
          
  
   <br/> • Staphylococcus saprophyticus (methicillin-susceptible isolates only) 
          
  
   <br/> • Streptococcus agalactiae
          
  
   <br/>
                           </content>Gram-negative bacteria
         
 
  <content styleCode="italics">
                              <br/> • Morganella morganii 
          
  
   <br/> • Proteus inconstans 
          
  
   <br/> • Proteus mirabilis 
          
  
   <br/> • Providencia rettgeri
          
  
   <br/> Anaerobic Bacteria :
          
  
   <br/>
                           </content>Gram-positive bacteria
         
 
  <content styleCode="italics">
                              <br/> • Peptococcus niger
         
 
  </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Susceptibility Testing</content>
                           <content styleCode="italics">
                              <br/> For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
         
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="e57f65d7-2414-f45b-e053-2995a90a19fa"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20211123"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="e57f65d7-2415-f45b-e053-2995a90a19fa"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Although lifetime studies in animals have not been performed to evaluate carcinogenic potential, no mutagenic activity was found for cefuroxime axetil in a battery of bacterial mutation tests. Positive results were obtained in an in vitro chromosome aberration assay; however, negative results were found in an in vivo micronucleus test at doses up to 1.5 g/kg. Fertility studies in rats (males dosed for 70 days prior to and through mating; females dosed 21 days prior to mating through lactation) at doses up to 1,000 mg/kg/day (9 times the MRHD based on body surface area) have revealed no adverse effects on fertility.</paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="e57f65d7-2416-f45b-e053-2995a90a19fa"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20211123"/>
               <component>
                  <section ID="Section_14.1">
                     <id root="e57f65d7-2417-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Acute Bacterial Maxillary Sinusitis</title>
                     <text>
                        <br/>
                        <paragraph>One adequate and well-controlled trial was performed in subjects with acute bacterial maxillary sinusitis. In this trial, each subject had a maxillary sinus aspirate collected by sinus puncture before treatment was initiated for presumptive acute bacterial sinusitis. All subjects had radiographic and clinical evidence of acute maxillary sinusitis. In the trial, the clinical effectiveness of cefuroxime axetil in treating acute maxillary sinusitis was comparable to an oral antimicrobial agent containing a specific β-lactamase inhibitor. However, microbiology data demonstrated cefuroxime axetil to be effective in treating acute bacterial maxillary sinusitis due only to Streptococcus pneumoniae or non-β-lactamase–producing Haemophilus influenzae. Insufficient numbers of β-lactamase–producing Haemophilus influenzae and Moraxella catarrhalis isolates were obtained in this trial to adequately evaluate the effectiveness of cefuroxime axetil in treating acute bacterial maxillary sinusitis due to these 2 organisms.
         
 
  <br/>
                           <br/>This trial randomized 317 adult subjects, 132 subjects in the U.S. and 185 subjects in South America. 
         
 
  <br/>Table 10 shows the results of the intent-to-treat analysis.
        

 </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Table 10. Clinical Effectiveness of Cefuroxime Axetil Tablets in the Treatment of Acute Bacterial Maxillary Sinusitis</content>
                        </paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="301">
                           <col width="19.9955761999558%"/>
                           <col width="19.9955761999558%"/>
                           <col width="19.9955761999558%"/>
                           <col width="19.9955761999558%"/>
                           <col width="20.017695200177%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  
            
    
     <br/>
                                    <content styleCode="bold"> </content>
                                 </td>
                                 <td colspan="2" styleCode="Rrule" valign="top">
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">U.S. Subjects</content>
                                    <sup>a</sup>
                                    <br/> 
           
   
    </td>
                                 <td colspan="2" styleCode="Rrule" valign="top"> 
            
    
     <content styleCode="bold">South American Subjects</content>
                                    <sup>b</sup>
                                    <br/> 
           
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 
            
    
     <content styleCode="bold">Cefuro xime</content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Axetil Tablets</content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">250 mg Twice</content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Daily (n = 49)</content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Control c</content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">(n = 43)</content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Cefuroxime</content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Axetil</content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Tablets 250</content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">mg Twice</content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Daily (n = 49)</content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Controlc</content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">(n = 43)</content>
                                    <br/> 
           
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Clinical success
            
    
     <br/> (cure + improvement)
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 65%
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 53%
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 77%
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 74%
            
    
     <br/> 
           
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Clinical cure
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 53%
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 44%
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 72%
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 64%
            
    
     <br/> 
           
   
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> Clinical improvement
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 12%
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 9%
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 5%
            
    
     <br/> 
           
   
    </td>
                                 <td styleCode="Rrule" valign="top"> 10%
            
    
     <br/> 
           
   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>
                           <sup>a</sup> 95% confidence interval around the success difference [-0.08, +0.32].
        

 </paragraph>
                        <br/>
                        <paragraph>
                           <sup>b</sup> 95% confidence interval around the success difference [-0.10, +0.16].
         
 
  <br/>
                           <sup>c</sup> Control was an antibacterial drug containing a β-lactamase inhibitor.
        

 </paragraph>
                        <br/>
                        <br/>
                        <paragraph>In this trial and in a supporting maxillary puncture trial, 15 evaluable subjects had non-β-lactamase–producing 
         
 
  <content styleCode="italics">Haemophilus influenzae</content> as the identified pathogen. Of these, 67% (10/15) had this pathogen eradicated. Eighteen (18) evaluable subjects had 
         
 
  <content styleCode="italics">Streptococcus pneumoniae</content> as the identified pathogen. Of these, 83% (15/18) had this pathogen eradicated. 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.2">
                     <id root="e57f65d7-2418-f45b-e053-2995a90a19fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Early Lyme Disease</title>
                     <text>
                        <paragraph>Two adequate and well-controlled trials were performed in subjects with early Lyme disease. All subjects presented with physician-documented erythema migrans, with or without systemic manifestations of infection. Subjects were assessed at 1 month posttreatment for success in treating early Lyme disease (Part I) and at 1 year posttreatment for success in preventing the progression to the sequelae of late Lyme disease (Part II).</paragraph>
                        <paragraph>A total of 355 adult subjects (181 treated with cefuroxime axetil and 174 treated with doxycycline) were randomized in the 2 trials, with diagnosis of early Lyme disease confirmed in 79% (281/355). The clinical diagnosis of early Lyme disease in these subjects was validated by 1) blinded expert reading of photographs, when available, of the pretreatment erythema migrans skin lesion, and 2) serologic confirmation (using enzyme-linked immunosorbent assay [ELISA] and immunoblot assay [“Western” blot]) of the presence of antibodies specific to 
         
 
  <content styleCode="italics">Borrelia burgdorferi</content>, the etiologic agent of Lyme disease. The efficacy data in Table 11 are specific to this “validated” patient subset, while the safety data below reflect the entire patient population for the 2 trials. Clinical data for evaluable subjects in the “validated” patient subset are shown in Table 11.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="bold"> Table 11. Clinical Effectiveness of Cefuroxime Axetil Tablets Compared with Doxycycline in the Treatment of Early Lyme Disease</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="582">
                           <col width="22.1604674362263%"/>
                           <col width="19.4527575887131%"/>
                           <col width="19.4670086931737%"/>
                           <col width="19.4527575887131%"/>
                           <col width="19.4670086931737%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top"> 
            
    
     <br/>
                                 </td>
                                 <td colspan="2" align="justify" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Part I (1 Month after 20 Days of Treatment)
             
     
      <sup>a </sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td colspan="2" align="justify" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Part II (1 Year after 20 Days of Treatment)
             
     
      <sup>b</sup>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top"> 
            
    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Cefuroxime Axetil Tablets </content>
                                    <br/>
                                    <content styleCode="bold"> 500 mg</content>
                                    <br/>
                                    <content styleCode="bold">Twice Daily </content>
                                    <br/>
                                    <content styleCode="bold">(n = 125) </content>
                                    <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Doxycycline 100 mg 3</content>
                                    <br/>
                                    <content styleCode="bold">Times Daily (n = 108) </content>
                                    <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Cefuroxime Axetil Tablets </content>
                                    <content styleCode="bold"> </content>
                                    <br/>
                                    <content styleCode="bold">500 mg</content>
                                    <content styleCode="bold"/>
                                    <br/>
                                    <content styleCode="bold"> Twice Daily (n = 105c) </content>
                                    <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Doxycycline 100 mg 3</content>
                                    <br/>
                                    <content styleCode="bold">Times Daily (n = 83c) </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Satisfactory clinical outcomed 
            
    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">91% 
            
    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">93% 
            
    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">84% 
            
    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">87% 
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="middle">Clinical cure/success 
            
    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">72% 
            
    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">73% 
            
    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">73% 
            
    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">73% 
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Lrule Rrule" valign="middle">Clinical improvement 
            
    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">19% 
            
    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">19% 
            
    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">10% 
            
    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">13% 
            
    
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup> 95% confidence interval around the satisfactory difference for Part I (-0.08, +0.05). 
        

 </paragraph>
                        <paragraph>
                           <sup>b </sup>95% confidence interval around the satisfactory difference for Part II (-0.13, +0.07). 
        

 </paragraph>
                        <paragraph>
                           <sup>c </sup>n’s include subjects assessed as unsatisfactory clinical outcomes (failure + recurrence) in Part I (cefuroxime axetil - 11 [5 failure, 6 recurrence]; doxycycline - 8 [6 failure, 2 recurrence]). 
        

 </paragraph>
                        <paragraph>
                           <sup>d </sup>Satisfactory clinical outcome includes cure + improvement (Part I) and success + improvement (Part II).
        

 </paragraph>
                        <paragraph>Cefuroxime axetil and doxycycline were effective in prevention of the development of sequelae of late Lyme disease. </paragraph>
                        <paragraph>While the incidence of drug-related gastrointestinal adverse reactions was similar in the 2 treatment groups (cefuroxime axetil - 13%; doxycycline - 11%), the incidence of drug-related diarrhea was higher in the cefuroxime axetil arm versus the doxycycline arm (11% versus 3%, respectively).</paragraph>
                     </text>
                     <effectiveTime value="20211123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="fbc19e7b-68b3-498e-e053-6394a90a5f04"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Cefuroxime axetil tablets,USP</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Cefuroxime Axetil Tablets,USP 500 mg of cefuroxime (as cefuroxime axetil), are blue, capsule-shaped, biconvex, film-coated tablets with 203'' debossed on one side and plain on the other side as follows:</paragraph>
                  <paragraph/>
                  <paragraph>14 Tablets/Bottle                      NDC 72789-035-14
  <br/>
                     <br/>
20 Tablets/Bottle                      NDC 72789-035-20
  <br/>
                     <br/>
60 Tablets/Bottle                      NDC 72789-035-60
  <br/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <br/>
                     <br/>
                     <content styleCode="bold">Store at 20° to 25°C (68° to 77°F).  [See USP controlled room temperature]. Replace cap securely after each opening.  </content>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20211123"/>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="e57f65d7-241a-f45b-e053-2995a90a19fa"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Allergic Reactions</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>Inform patients that cefuroxime axetil is a cephalosporin that can cause allergic reactions in some individuals 
       
 
  <content styleCode="italics">[see Warnings and Precautions (
        
  
   <linkHtml href="#Section_5.1">5.1</linkHtml>)]
       
 
  </content>.
      

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <content styleCode="underline">
                           <content styleCode="italics">
                              <content styleCode="underline">Clostridioides</content>
                           </content> difficile
        
  
   </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="underline">-</content>
                     </content>
                     <content styleCode="underline">Associated Diarrhea</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>Inform patients that diarrhea is a common problem caused by antibacterials, and it usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken their last dose of the antibacterial. If this occurs, advise patients to contact their physician as soon as possible.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">Crushing Tablets</content>
                  </paragraph>
                  <paragraph>Instruct patients to swallow the tablet whole, without crushing the tablet. Patients who cannot swallow the tablet whole should receive the oral suspension.</paragraph>
                  <paragraph>
                     <content styleCode="bold">  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Drug Resistance</content>
                  </paragraph>
                  <paragraph>Inform patients that antibacterial drugs, including cefuroxime axetil, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cefuroxime axetil is prescribed to treat a bacterial infection, inform patients that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefuroxime axetil or other antibacterial drugs in the future.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Alkem Laboratories Ltd.,</content>
                  </paragraph>
                  <paragraph> INDIA.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                  </paragraph>
                  <paragraph>Ascend Laboratories, LLC
       
 
  <br/> Parsippany, NJ 07054
       
 
  <br/>
                     <content styleCode="bold">Revised: November, 2021
        
  
   <br/> PT 0996-08
       
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20211123"/>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="303d9fde-32b3-64de-e063-6394a90a1f27"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">CEFUROXIME
   <br/>
                        <br/>
AXETIL TABLETS, USP
   <br/>
                        <br/>
500 mg
   <br/>
                        <br/>
Rx only 
  </content>
                     <br/>
                     <renderMultiMedia referencedObject="img_303d9cb8-269c-5fd2-e063-6394a90a88da"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20211123"/>
               <component>
                  <observationMedia ID="img_303d9cb8-269c-5fd2-e063-6394a90a88da">
                     <text>image</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="72789035.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>